Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by AstraZeneca < Previous 1 2 3 4 5 6 Next > AIRSUPRA™ (PT027) approved in the US for asthma January 11, 2023 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca Awards $4M to Nonprofit Organizations to Advance Health Equity December 13, 2022 From AstraZeneca Via Business Wire Tickers AZN Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant) December 08, 2022 From AstraZeneca Via Business Wire Tickers AZN Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer December 08, 2022 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03 December 07, 2022 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022 November 30, 2022 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022 November 22, 2022 From AstraZeneca Via Business Wire Tickers AZN IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer November 11, 2022 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca EVUSHELD Named on TIME’s List of the Best Inventions of 2022 November 10, 2022 From AstraZeneca Via Business Wire Tickers AZN PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma November 09, 2022 From AstraZeneca Via Business Wire Tickers AZN Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer October 26, 2022 From AstraZeneca Via Business Wire Tickers AZN Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancer October 26, 2022 From AstraZeneca Via Business Wire Tickers AZN IMJUDO® (tremelimumab) in Combination With IMFINZI® (durvalumab) Approved in the US for Patients With Unresectable Liver Cancer October 24, 2022 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca Announces Winners of Fourth Annual Cancer Community Awards October 20, 2022 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19 September 15, 2022 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional follow-up September 12, 2022 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer September 11, 2022 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three years vs. chemotherapy September 11, 2022 From AstraZeneca Via Business Wire Tickers AZN TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer September 11, 2022 From AstraZeneca Via Business Wire Tickers AZN LYNPARZA® (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials September 09, 2022 From AstraZeneca Via Business Wire Tickers AZN IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer September 05, 2022 From AstraZeneca Via Business Wire Tickers AZN New data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure August 27, 2022 From AstraZeneca Via Business Wire Tickers AZN FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial August 27, 2022 From AstraZeneca Via Business Wire Tickers AZN AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022 August 24, 2022 From AstraZeneca Via Business Wire Tickers AZN LYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer August 16, 2022 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer August 12, 2022 From AstraZeneca Via Business Wire Tickers AZN TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial August 08, 2022 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer August 05, 2022 From AstraZeneca Via Business Wire Tickers AZN CALQUENCE® (acalabrutinib) tablet formulation approved in the US across current indications August 05, 2022 From AstraZeneca Via Business Wire Tickers AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer July 25, 2022 From AstraZeneca Via Business Wire Tickers AZN < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.